HAE
HAEMONETICS CORP
NYSE · Healthcare · Medical - Instruments & Supplies · US
$126.22
+4.94%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$122.16
From 52W high+0.00%
Volume295916.00
Market cap$5.74B
P/E (TTM)61.3x
P/S (TTM)4.2x
Div yield—
Key dataNov 4, 2026
Open
$122.16
From 52W high
+0.00%
Volume
295916.00
Market cap
$5.74B
ValuationView details →
P/E (Fwd)
22.3x
EV/EBITDA
25.6x
P/E (TTM)
61.3x
RSI (14)
73.3
MomentumView details →
1D Return
+4.94%
YTD Return
+56.91%
SummaryUpdated Jun 1, 2026
Haemonetics Corporation (NASDAQ:HAE) is a Boston-based healthcare company founded in 1971 that specializes in blood and plasma management technologies. The company has evolved from its origins in blood collection to become a leading provider of automated medical devices, software systems, and disposable products that help healthcare providers and plasma collection centers manage blood components more efficiently. Haemonetics went public in 1991 and has since grown through both organic expansion and strategic acquisitions to serve three primary markets: plasma collection, blood centers, and hospitals worldwide.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration approved HAEMONETICS CORP’s PerQseal Elite vascular closure system for large-bore arterial procedures in the United States.16d agoHAEMONETICS CORP shares rose more than 13% to $115.20 on Thursday.27d agoHaemonetics Corporation announced it will publish its second quarter fiscal year 2027 financial results on November 5, 2026.35d ago